Roseomonas gilardii Bacteremia in a Patient With HbSβ0-thalassemia: Clinical Implications and Literature Review.


Journal

Journal of pediatric hematology/oncology
ISSN: 1536-3678
Titre abrégé: J Pediatr Hematol Oncol
Pays: United States
ID NLM: 9505928

Informations de publication

Date de publication:
07 2020
Historique:
pubmed: 6 4 2019
medline: 13 4 2021
entrez: 6 4 2019
Statut: ppublish

Résumé

Roseomonas gilardii is a Gram-negative coccobacillus identified in immunocompromised pediatric patients. A 5-year-old male with a history of HbSβ thalassemia status postsurgical splenectomy presented to the emergency department with fever. Blood cultures grew R. gilardii at 63 hours, but the patient had been discharged home at 48 hours. The patient was readmitted for repeat cultures and initiated on meropenem for 10 days as Roseomonas spp. are often resistant to third generation cephalosporins. R. gilardii is a rare cause of bacteremia in immunocompromised patients. Clinicians should consider Roseomonas in slow growing Gram-negative rod bacteremias, and consider meropenem as empiric coverage.

Identifiants

pubmed: 30951022
doi: 10.1097/MPH.0000000000001476
pmc: PMC7724631
mid: NIHMS1523398
doi:

Types de publication

Case Reports Journal Article Research Support, N.I.H., Extramural Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

e385-e387

Subventions

Organisme : NHLBI NIH HHS
ID : K23 HL127100
Pays : United States

Références

Pediatr Blood Cancer. 2018 Nov;65(11):e27379
pubmed: 30070043
Int J Infect Dis. 2010 Jan;14(1):e2-e12
pubmed: 19497774
South Med J. 1985 Mar;78(3):310-1
pubmed: 3975746
Ann Lab Med. 2016 Jul;36(4):367-370
pubmed: 27139611
Biomed Pharmacother. 1990;44(3):153-8
pubmed: 2204448
J Clin Microbiol. 2010 Aug;48(8):3027-9
pubmed: 20534804
Diagn Microbiol Infect Dis. 2012 Mar;72(3):199-203
pubmed: 22209515
J Clin Microbiol. 2002 Dec;40(12):4789-91
pubmed: 12454198
Rev Bras Hematol Hemoter. 2018 Jan - Mar;40(1):37-42
pubmed: 29519371
J Clin Microbiol. 1993 Dec;31(12):3275-83
pubmed: 8308122
Blood. 2012 Feb 23;119(8):1915-21
pubmed: 22130804
J Pediatr Hematol Oncol. 2014 Apr;36(3):e165-8
pubmed: 23669726
Int J Infect Dis. 2001;5(3):170-1
pubmed: 11724677
IDCases. 2018 Nov 13;14:e00469
pubmed: 30479963
N Engl J Med. 1986 Jun 19;314(25):1593-9
pubmed: 3086721
Blood. 1994 Jul 15;84(2):643-9
pubmed: 7517723
Biochim Biophys Acta. 2009 Jul;1790(7):600-5
pubmed: 18675317
Clin Infect Dis. 1996 Oct;23(4):729-33
pubmed: 8909835
Pediatr Blood Cancer. 2006 Apr;46(4):514-6
pubmed: 15782406

Auteurs

Charles Schlappi (C)

Department of Pediatrics, Division of Pediatric Hematology and Oncology.

Joshua D Bernstock (JD)

School of Medicine.
Medical Scientist Training Program.

Wilson Ricketts (W)

School of Medicine.

Garrett A Nix (GA)

School of Medicine.

Claudette Poole (C)

Department of Pediatrics, Division of Pediatric Infectious Diseases, University of Alabama at Birmingham, Birmingham, AL.

Jeffrey Lebensburger (J)

Department of Pediatrics, Division of Pediatric Hematology and Oncology.

Gregory K Friedman (GK)

Department of Pediatrics, Division of Pediatric Hematology and Oncology.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH